Abstract
Background
This study was to investigate the value of 10 serum inflammatory cytokines for predicting clinical response to celecoxib in ankylosing spondylitis (AS) patients.
Methods
Totally, 103 active AS patients who underwent celecoxib treatment for 12 weeks were enrolled. Then, pre-treatment serum TNF-α, IL-1β, IL-6, IL-8, IL-17A, IL-21, IL-23, IL-32, ICAM-1, and VEGF were detected by enzyme-linked immunosorbent assay. Besides, the ASAS 20 response was assessed at week 2 (W2), week 6 (W6), and week 12 (W12). Based on the ASAS 20 response at W12, patients were divided into responders and non-responders.
Results
After celecoxib treatment, 53 (51.3%), 58 (56.3%), and 60 (58.3%) patients achieved ASAS 20 response at W2, W6, and W12, respectively. Furthermore, IL-1β (P = 0.019), IL-6 (P = 0.004), and IL-17A (P = 0.007) levels were higher, while TNF-α (P = 0.086), IL-8 (P = 0.143), IL-21 (P = 0.687), IL-23 (P = 0.329), IL-32 (P = 0.216), ICAM-1 (P = 0.119), and VEGF (P = 0.732) levels were similar in responders compared with non-responders. Subsequent multivariate logistic regression analysis revealed that among these inflammatory cytokines, only IL-6 (P = 0.019) independently predicted higher ASAS 20 response to celecoxib at W12, and it had a fair value for predicting ASAS 20 response to celecoxib at W12 (area under the curve: 0.666, 95% confidence interval: 0.561–0.771) by receiver-operating characteristic curve analysis.
Conclusion
Serum IL-1β, IL-6, and IL-17A serve as indicators for predicting clinical response to celecoxib in AS patients, which may assist with the optimization of personalized treatment.
Similar content being viewed by others
References
Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390
Bidad K, Gracey E, Hemington KS et al (2017) Pain in ankylosing spondylitis: a neuro-immune collaboration. Nat Rev Rheumatol 13(7):410–420
Huang F, Gu J, Liu Y et al (2014) Efficacy and safety of celecoxib in Chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp 76:126–133
Tam LS, Gu J, Yu D (2010) Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 6(7):399–405
Poddubnyy DA, Song IH, Sieper J (2008) The safety of celecoxib in ankylosing spondylitis treatment. Expert Opin Drug Saf 7(4):401–409
McCormack PL (2011) Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71(18):2457–2489
van der Linden S (2008) Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs. Wien Med Wochenschr 158(7–8):195–199
Sveaas SH, Berg IJ, Provan SA et al (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44(2):118–124
Sezer U, Erciyas K, Pehlivan Y et al (2012) Serum cytokine levels and periodontal parameters in ankylosing spondylitis. J Periodontal Res 47(3):396–401
Wen JT, Zhang DH, Fang PF et al (2017) Role of Th1/Th2 cytokines in the diagnosis and prognostic evaluation of ankylosing spondylitis. Genet Mol Res 16(1)
Yan Y, Guo TM, Zhu C (2018) Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis. Biochem Cell Biol 96(4):450–456
Pan JE, Xiong FL, Chen G et al (2017) Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: a comparative study. Biomed Pharmacother 95:1549–1555
Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl 2):ii1–i44
Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886
Stone MA, Payne U, Pacheco-Tena C et al (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63(1):84–87
Falkenbach A, Herold M, Wigand R (2000) Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year? Rheumatol Int 19(4):149–151
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The approval of this study was obtained from the Institutional Review Board of our hospital. Written informed consents were collected from all enrolled patients.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, Y., Ning, C., Zhou, H. et al. Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients. Ir J Med Sci 190, 631–638 (2021). https://doi.org/10.1007/s11845-020-02366-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-020-02366-5